Company Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity.
The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity.
The company was incorporated in 2016 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Ms. Amy L. Burroughs M.B.A. |
Contact Details
Address: 1065 East Hillsdale Blvd., Suite 100 Foster City, California 94404 United States | |
| Phone | 650-525-5535 EXT.101 |
| Website | ternspharma.com |
Stock Details
| Ticker Symbol | TERN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001831363 |
| CUSIP Number | 880881107 |
| ISIN Number | US8808811074 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Erin Quirk M.D. | President and Head of Research & Development |
| Seokho Yoon Esq. | Chief Operating Officer, General Counsel and Secretary |
| Amy L. Burroughs M.B.A. | Chief Executive Officer and Director |
| Dr. Mark Joseph Vignola Ph.D. | Chief Financial Officer and Treasurer |
| Dr. Jeffrey R. Jasper Ph.D. | Senior Vice President and Head of Research |
| Dr. Emil T. Kuriakose M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |